Lacosamide Lowers Valproate and Levetiracetam Levels.
Lacosamide (LCM) due to no known drug interaction and the absence of metabolic enzyme induction is a good candidate for an add-on medication, especially in combination with lamotrigine, levetiracetam (LEV), oxcarbazepine, topiramate, and valproic acid (VPA). Here we report for the first time, to our knowledge, that LCM can lower VPA and LEV serum levels. At present, there are no known explicable mechanisms of action of LCM, which lowers VPA and LEV. Here observed drug interaction of LCM is of clinical significance, which might be useful for other colleagues in the field.
Department of Pediatric Neurology, Center for Chronically Sick Children, Charité University Medicine Berlin, Berlin, Germany.
Maria
M
Tountopoulou
Department of Pediatric Neurology, Center for Chronically Sick Children, Charité University Medicine Berlin, Berlin, Germany.
Bernhard
B
Weschke
Department of Pediatric Neurology, Center for Chronically Sick Children, Charité University Medicine Berlin, Berlin, Germany.|Institute of Cell Biology and Neurobiology, Charité University Medicine Berlin, Berlin, Germany.
Angela M
AM
Kaindl
D000081:Acetamides / Q000627:therapeutic use*; D000293:Adolescent; D000927:Anticonvulsants / Q000097:blood* / Q000627:therapeutic use; D001932:Brain Neoplasms / Q000150:complications; D004347:Drug Interactions; D004828:Epilepsies, Partial / Q000150:complications / Q000188:drug therapy; D006801:Humans; D000078334:Lacosamide; D000077287:Levetiracetam; D018302:Neoplasms, Neuroepithelial / Q000150:complications; D010889:Piracetam / Q000031:analogs & derivatives* / Q000097:blood / Q000627:therapeutic use; D012640:Seizures / Q000188:drug therapy / Q000209:etiology; D014635:Valproic Acid / Q000097:blood* / Q000627:therapeutic use
D000081:Acetamides; D000927:Anticonvulsants; D000077287:Levetiracetam; D000078334:Lacosamide; D014635:Valproic Acid; D010889:Piracetam